DE60216770T2 - Ionisches und nicht-ionisches radiographisches kontrastmittel zur verwendung in der kombinierten roentgen- und kernspintomographiediagnostik - Google Patents
Ionisches und nicht-ionisches radiographisches kontrastmittel zur verwendung in der kombinierten roentgen- und kernspintomographiediagnostik Download PDFInfo
- Publication number
- DE60216770T2 DE60216770T2 DE60216770T DE60216770T DE60216770T2 DE 60216770 T2 DE60216770 T2 DE 60216770T2 DE 60216770 T DE60216770 T DE 60216770T DE 60216770 T DE60216770 T DE 60216770T DE 60216770 T2 DE60216770 T2 DE 60216770T2
- Authority
- DE
- Germany
- Prior art keywords
- use according
- water
- mri
- compounds
- iopamidol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002872 contrast media Substances 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 238000012546 transfer Methods 0.000 claims description 27
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 claims description 24
- 229960004647 iopamidol Drugs 0.000 claims description 23
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 22
- 230000005415 magnetization Effects 0.000 claims description 16
- 230000005291 magnetic effect Effects 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 claims description 7
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 claims description 7
- 229960000554 metrizamide Drugs 0.000 claims description 7
- 238000012307 MRI technique Methods 0.000 claims description 6
- ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 claims description 6
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical class CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 claims description 5
- 238000003384 imaging method Methods 0.000 claims description 5
- 229960002603 iopromide Drugs 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 229960005223 diatrizoic acid Drugs 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- HXLVCCRPDYIRRX-UHFFFAOYSA-N iodoamine Chemical compound IN HXLVCCRPDYIRRX-UHFFFAOYSA-N 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- DFDJVFYYDGMDTB-BIYVAJLZSA-N 1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[[(3s,4r,5s)-3,4,5,6-tetrahydroxy-2-oxohexanoyl]amino]benzene-1,3-dicarboxamide Chemical compound OCC(O)CNC(=O)C1=C(I)C(NC(=O)C(=O)[C@@H](O)[C@H](O)[C@@H](O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I DFDJVFYYDGMDTB-BIYVAJLZSA-N 0.000 claims description 3
- ODYPLCHSCOJEIZ-GMYJMXFCSA-N 3-[acetyl(methyl)amino]-n-(2-hydroxyethyl)-2,4,6-triiodo-5-[[(2s,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoyl]amino]benzamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=C(I)C(C(=O)NCCO)=C1I ODYPLCHSCOJEIZ-GMYJMXFCSA-N 0.000 claims description 3
- NNZBBKHCMKTQJQ-UWVGGRQHSA-N 3-n-(1,3-dihydroxypropan-2-yl)-1-n-[3-[[3-(1,3-dihydroxypropan-2-ylcarbamoyl)-5-[[(2s)-2-hydroxypropanoyl]amino]-2,4,6-triiodobenzoyl]amino]-2-hydroxypropyl]-5-[[(2s)-2-hydroxypropanoyl]amino]-2,4,6-triiodobenzene-1,3-dicarboxamide Chemical compound OCC(CO)NC(=O)C1=C(I)C(NC(=O)[C@@H](O)C)=C(I)C(C(=O)NCC(O)CNC(=O)C=2C(=C(C(=O)NC(CO)CO)C(I)=C(NC(=O)[C@H](C)O)C=2I)I)=C1I NNZBBKHCMKTQJQ-UWVGGRQHSA-N 0.000 claims description 3
- YLPBXIKWXNRACS-UHFFFAOYSA-N iobitridol Chemical compound OCC(O)CN(C)C(=O)C1=C(I)C(NC(=O)C(CO)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I YLPBXIKWXNRACS-UHFFFAOYSA-N 0.000 claims description 3
- 229960004108 iobitridol Drugs 0.000 claims description 3
- 229950003517 iofratol Drugs 0.000 claims description 3
- 229950006335 ioglunide Drugs 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 238000000264 spin echo pulse sequence Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 41
- 238000000034 method Methods 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- 230000007423 decrease Effects 0.000 description 10
- 125000003368 amide group Chemical group 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940039231 contrast media Drugs 0.000 description 3
- 238000012631 diagnostic technique Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000001678 irradiating effect Effects 0.000 description 3
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 3
- 238000009608 myelography Methods 0.000 description 3
- -1 triiodoiodinated aromatic radicals Chemical class 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 239000002616 MRI contrast agent Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000001491 aromatic compounds Chemical class 0.000 description 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- HZHFFEYYPYZMNU-UHFFFAOYSA-K gadodiamide Chemical compound [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC HZHFFEYYPYZMNU-UHFFFAOYSA-K 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000193 iodinated contrast media Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000000079 presaturation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000007487 urography Methods 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 1
- CORFWQGVBFFZHF-UHFFFAOYSA-N 2-iodohippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1I CORFWQGVBFFZHF-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 238000000685 Carr-Purcell-Meiboom-Gill pulse sequence Methods 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- UXIGWFXRQKWHHA-UHFFFAOYSA-N Iotalamic acid Chemical compound CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I UXIGWFXRQKWHHA-UHFFFAOYSA-N 0.000 description 1
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000002584 aortography Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000013155 cardiography Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical class CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- PVBALTLWZVEAIO-UHFFFAOYSA-N diodone Chemical compound OC(=O)CN1C=C(I)C(=O)C(I)=C1 PVBALTLWZVEAIO-UHFFFAOYSA-N 0.000 description 1
- SIZXNBZGPPPFHM-UHFFFAOYSA-L disodium;3-[[6-(3-carboxylato-2,4,6-triiodoanilino)-6-oxohexanoyl]amino]-2,4,6-triiodobenzoate Chemical class [Na+].[Na+].[O-]C(=O)C1=C(I)C=C(I)C(NC(=O)CCCCC(=O)NC=2C(=C(C([O-])=O)C(I)=CC=2I)I)=C1I SIZXNBZGPPPFHM-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- LGMLJQFQKXPRGA-VPVMAENOSA-K gadopentetate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O LGMLJQFQKXPRGA-VPVMAENOSA-K 0.000 description 1
- RYHQMKVRYNEBNJ-BMWGJIJESA-K gadoterate meglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 RYHQMKVRYNEBNJ-BMWGJIJESA-K 0.000 description 1
- GFSTXYOTEVLASN-UHFFFAOYSA-K gadoteric acid Chemical compound [Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 GFSTXYOTEVLASN-UHFFFAOYSA-K 0.000 description 1
- DPNNNPAKRZOSMO-UHFFFAOYSA-K gadoteridol Chemical compound [Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 DPNNNPAKRZOSMO-UHFFFAOYSA-K 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- DGIAUNUPXILTJW-VRWDCWMNSA-N iodipamide dimeglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)C1=C(I)C=C(I)C(NC(=O)CCCCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I DGIAUNUPXILTJW-VRWDCWMNSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960000780 iomeprol Drugs 0.000 description 1
- NJKDOADNQSYQEV-UHFFFAOYSA-N iomeprol Chemical compound OCC(=O)N(C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NJKDOADNQSYQEV-UHFFFAOYSA-N 0.000 description 1
- 229960000824 iopentol Drugs 0.000 description 1
- IUNJANQVIJDFTQ-UHFFFAOYSA-N iopentol Chemical compound COCC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I IUNJANQVIJDFTQ-UHFFFAOYSA-N 0.000 description 1
- 229960000929 iotalamic acid Drugs 0.000 description 1
- 229960004537 ioversol Drugs 0.000 description 1
- UUMLTINZBQPNGF-UHFFFAOYSA-N ioxilan Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCCO)=C(I)C(C(=O)NCC(O)CO)=C1I UUMLTINZBQPNGF-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229940124280 l-arginine Drugs 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 1
- 229960004712 metrizoic acid Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 231100001224 moderate toxicity Toxicity 0.000 description 1
- 239000003690 nonionic contrast media Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0461—Dispersions, colloids, emulsions or suspensions
- A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI001706A ITMI20011706A1 (it) | 2001-08-03 | 2001-08-03 | Agenti di contrasto radiografici ionici e non ionici, utilizzabili per l'indagine diagnostica combinata tramite raggi-x e risonanza magnetic |
| ITMI20011706 | 2001-08-03 | ||
| PCT/EP2002/008183 WO2003013616A1 (en) | 2001-08-03 | 2002-07-23 | Ionic and non-ionic radiographic contrast agents for use in combined x-ray and nuclear magnetic resonance diagnostics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60216770D1 DE60216770D1 (de) | 2007-01-25 |
| DE60216770T2 true DE60216770T2 (de) | 2007-04-12 |
Family
ID=11448229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60216770T Expired - Lifetime DE60216770T2 (de) | 2001-08-03 | 2002-07-23 | Ionisches und nicht-ionisches radiographisches kontrastmittel zur verwendung in der kombinierten roentgen- und kernspintomographiediagnostik |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8211404B2 (enExample) |
| EP (1) | EP1411992B1 (enExample) |
| JP (1) | JP4310187B2 (enExample) |
| AT (1) | ATE347912T1 (enExample) |
| DE (1) | DE60216770T2 (enExample) |
| DK (1) | DK1411992T3 (enExample) |
| ES (1) | ES2278946T3 (enExample) |
| IT (1) | ITMI20011706A1 (enExample) |
| WO (1) | WO2003013616A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070015517A (ko) | 2004-03-11 | 2007-02-05 | 말린크로트, 인코포레이티드 | 요오드화된 단량체 및 이량체의 혼합물을 포함하는 ｘ-선조영제 제형 |
| DE102005028882A1 (de) * | 2005-06-22 | 2007-01-04 | Siemens Ag | Lösung und Verfahren zum Unterstützen der Bildgebung an einem Patienten |
| US7683617B2 (en) * | 2005-07-21 | 2010-03-23 | Johns Hopkins University | Non-invasive MRI measurement of tissue glycogen |
| US20100121188A1 (en) * | 2006-10-10 | 2010-05-13 | Sandhu Gurpreet S | Reducing contrast agent-induced toxicity |
| EP2200971B1 (en) * | 2007-10-12 | 2013-04-24 | GE Healthcare AS | Contrast agents |
| WO2009060021A1 (en) * | 2007-11-07 | 2009-05-14 | Ge Healthcare As | Contrast agents |
| DE102007058220A1 (de) | 2007-12-03 | 2009-06-04 | Bayer Schering Pharma Aktiengesellschaft | Dimere macrocyclisch substituierte Benzolderivate |
| EP2231200A1 (en) * | 2007-12-05 | 2010-09-29 | GE Healthcare AS | Contrast agents |
| EP2245003A2 (en) * | 2008-02-27 | 2010-11-03 | GE Healthcare AS | Contrast agents |
| EP2243767A1 (en) * | 2009-04-21 | 2010-10-27 | Bracco Imaging S.p.A | Process for the iodination of aromatic compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2541272A1 (fr) * | 1983-02-23 | 1984-08-24 | Guerbet Sa | Composes bromes et produits opacifiants en contenant |
| CA2187427A1 (en) | 1995-02-24 | 1996-08-29 | Herve Tournier | Liposome suspensions as blood pool imaging contrast agents |
| US5648536A (en) * | 1995-06-07 | 1997-07-15 | Dunn; Thomas Jeffrey | Process for producing ioversol |
| DE69920425T2 (de) | 1998-04-09 | 2005-09-29 | Amersham Health As | Verwendung von teilchenförmigen kontrastmitteln in der diagnostischen bilderzeugung zur untersuchung physiologischer parameter |
| EP1178837A2 (en) * | 1999-04-21 | 2002-02-13 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method for enhancing contrast produced by mri |
| FR2794744B1 (fr) * | 1999-06-09 | 2001-09-21 | Guerbet Sa | Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale |
-
2001
- 2001-08-03 IT IT2001MI001706A patent/ITMI20011706A1/it unknown
-
2002
- 2002-07-23 US US10/485,878 patent/US8211404B2/en not_active Expired - Fee Related
- 2002-07-23 AT AT02758379T patent/ATE347912T1/de active
- 2002-07-23 EP EP02758379A patent/EP1411992B1/en not_active Expired - Lifetime
- 2002-07-23 DK DK02758379T patent/DK1411992T3/da active
- 2002-07-23 ES ES02758379T patent/ES2278946T3/es not_active Expired - Lifetime
- 2002-07-23 JP JP2003518618A patent/JP4310187B2/ja not_active Expired - Fee Related
- 2002-07-23 WO PCT/EP2002/008183 patent/WO2003013616A1/en not_active Ceased
- 2002-07-23 DE DE60216770T patent/DE60216770T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005505527A (ja) | 2005-02-24 |
| US8211404B2 (en) | 2012-07-03 |
| DE60216770D1 (de) | 2007-01-25 |
| ATE347912T1 (de) | 2007-01-15 |
| JP4310187B2 (ja) | 2009-08-05 |
| ES2278946T3 (es) | 2007-08-16 |
| US20050113675A1 (en) | 2005-05-26 |
| ITMI20011706A1 (it) | 2003-02-03 |
| EP1411992A1 (en) | 2004-04-28 |
| DK1411992T3 (da) | 2007-04-10 |
| WO2003013616A1 (en) | 2003-02-20 |
| WO2003013616A8 (en) | 2004-04-08 |
| ITMI20011706A0 (it) | 2001-08-03 |
| EP1411992B1 (en) | 2006-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69427931T2 (de) | Verfahren zur Bilderzeugung mittels magnetischer Resonanz von geänderten Dipolmomenten | |
| US5324503A (en) | Iodo-phenylated chelates for x-ray contrast | |
| DE69318727T2 (de) | Wässerige einspritzbare Zusammensetzungen verwendbar zur Radiodiagnose enthaltenden jodierten aromatischen Verbindungen zur Verwendung als Röntgenkontrastmittel | |
| DE69007575T2 (de) | Kontrastmittel. | |
| DE68922485T2 (de) | Verfahren zur einführung von sauerstoff-17 in gewebe zur bildformung in einem magnetischen resonanzbildformungssystem. | |
| EP0071564B1 (de) | Paramagnetische Komplexsalze, deren Herstellung und Verwendung bei der NMR-Diagnostik | |
| DE2814038C3 (de) | Mit einem Radionuklid für radioaktive Tests markierbares Material | |
| Gonsette | Biologic tolerance of the central nervous system to metrizamide | |
| DE68908185T2 (de) | Chelat-zusammensetzung. | |
| DE60216770T2 (de) | Ionisches und nicht-ionisches radiographisches kontrastmittel zur verwendung in der kombinierten roentgen- und kernspintomographiediagnostik | |
| SK278621B6 (en) | The contrasting agent | |
| DE69020208T2 (de) | Kontrastmittel. | |
| EP1960002B1 (de) | Wässrige dispersion von superparamagnetischen eindomänenteilchen, deren herstellung und verwendung zur diagnose und therapie | |
| US8518373B2 (en) | Ionic and non-ionic radiographic contrast agents for use in combined X-ray and nuclear magnetic resonance diagnostics | |
| EP1307237B9 (de) | Perfluoralkylhaltige komplexe mit polaren resten, verfahren zu deren herstellung und ihre verwendung | |
| DE19808079A1 (de) | Hydroxyethylstärke-Konjugate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel | |
| Schmitz et al. | Evaluation of gadobutrol in a rabbit model as a new lanthanide contrast agent for computed tomography | |
| DE60026743T2 (de) | Verwendung von Kontrastmitteln zur Herstellung eines Diagnostischen Mittels für die Darmlumenbildgebung | |
| EP1017424A1 (de) | Lipophile metall-komplexe für nekrose und infarkt-imaging | |
| DE69732370T2 (de) | Spinresonanz kontrastmittel für das blut | |
| WO1996027394A1 (de) | Verwendung von ferriten zur bestimmung der perfusion von menschlichem gewebe mittels mr-diagnostik | |
| WO2007128567A1 (de) | Verwendung von perfluoralkylhaltigen metallkomplexen als kontrastmittel zur diagnose der alzheimer krankheit | |
| DE10040380B4 (de) | Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques | |
| Gonsette | The neurotoxicity of water-soluble contrast media: actual concepts and future | |
| DE19627309C2 (de) | Wäßrige injizierbare Formulierungen verwendbar als Kontrastmittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |